EconPapers    
Economics at your fingertips  
 

PharmacoEconomics

1997 - 2021

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.


Volume 39, issue 1, 2021

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods pp. 1-17 Downloads
Rick A. Vreman, Joost W. Geenen, Saskia Knies, Aukje K. Mantel-Teeuwisse, Hubert G. M. Leufkens and Wim G. Goettsch
Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier pp. 19-24 Downloads
Christopher McCabe, Giovanni Tramonti, Andrew Sutton, Peter Hall and Mike Paulden
Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions pp. 25-61 Downloads
Ruth A. Lewis, Dyfrig Hughes, Alex J. Sutton and Clare Wilkinson
Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review pp. 63-80 Downloads
Thomas Lung, Lei Si, Richard Hooper and Gian Luca Di Tanna
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review pp. 81-97 Downloads
Akira Yuasa, Naohiro Yonemoto, Michael LoPresti and Shunya Ikeda
The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best–Worst Scaling Experiment pp. 99-108 Downloads
Irina Pokhilenko, Luca M. M. Janssen, Mickael Hiligsmann, Silvia M. A. A. Evers, Ruben M. W. A. Drost, Aggie T. G. Paulus and Leonarda G. M. Bremmers
Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions pp. 109-119 Downloads
Linda Yamoah, Nick Dragojlovic, Alesha Smith, Larry D. Lynd and Carlo A. Marra
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia pp. 121-131 Downloads
Carla Mamolo, Verna Welch, Roland B. Walter, Joseph C. Cappelleri, James Brockbank, Matthew Cawson, Chris Knight and Michele Wilson
Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions” pp. 133-135 Downloads
Bram L. T. Ramaekers, Ben Wijnen, Nigel Armstrong, Svenja Petersohn, Talitha Feenstra, Junfeng Wang and Manuela A. Joore
Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions” pp. 137-138 Downloads
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri and Volker Foos

Volume 38, issue 12, 2020

The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D? pp. 1283-1288 Downloads
David G. T. Whitehurst, John E. Brazier, Rosalie Viney and Brendan J. Mulhern
Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer? pp. 1289-1295 Downloads
Luke B. Connelly and Stephen Birch
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies pp. 1297-1308 Downloads
Aris Angelis, Huseyin Naci and Allan Hackshaw
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal pp. 1309-1318 Downloads
Caroline Farmer, Ash Bullement, David Packman, Linda Long, Sophie Robinson, Elham Nikram, Anthony J. Hatswell, G. J. Melendez-Torres and Louise Crathorne
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach pp. 1319-1331 Downloads
Jessica Ochalek, Haiyin Wang, Yuanyuan Gu, James Lomas, Henry Cutler and Chunlin Jin
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles pp. 1333-1343 Downloads
Ching-Yu Wang, Phuong N. Pham, Thuy N. Thai and Joshua D. Brown
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China pp. 1345-1358 Downloads
Lei Tian, Xiaomo Xiong, Qiang Guo, Yixi Chen, Luying Wang, Peng Dong and Aixia Ma
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups pp. 1359-1372 Downloads
Shweta Mital and Hai V. Nguyen
Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” pp. 1373-1374 Downloads
Richard Manning
Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” pp. 1375-1376 Downloads
William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti and Gerard F. Anderson
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018 pp. 1377-1377 Downloads
David D. Kim, Madison C. Silver, Natalia Kunst, Joshua T. Cohen, Daniel A. Ollendorf and Peter J. Neumann

Volume 38, issue 11, 2020

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19? pp. 1149-1151 Downloads
Kamal Desai, Eric Druyts, Kevin Yan and Chakrapani Balijepalli
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers pp. 1153-1164 Downloads
Risha Gidwani and Louise Russell
Integrative Review of Managed Entry Agreements: Chances and Limitations pp. 1165-1185 Downloads
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Maurílio Souza Cazarim, Laís Lessa Neiva Pantuzza, Nelio Gomes Ribeiro-Junior, André Luiz Pereira, Marcus Carvalho Borin, Isabella Figueiredo Zuppo, Roberto Iunes, Tomas Pippo, Renata Curi Hauegen, Carlos Vassalo, Tracey-Lea Laba, Steven Simoens, Sergio Márquez, Carolina Gomez, Luka Voncina, Gisbert W. Selke, Livio Garattini, Hye-Young Kwon, Jolanta Gulbinovic, Aneta Lipinska, Maciej Pomorski, Lindsay McClure, Jurij Fürst, Rosana Gambogi, Carla Hernandez Ortiz, Vânia Cristina Canuto Santos, Denizar Vianna Araújo, Vânia Eloisa Araujo, Francisco de Assis Acurcio, Juliana Alvares-Teodoro and Augusto Afonso Guerra-Junior
Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer pp. 1187-1200 Downloads
Erik F. Blom, Kevin ten Haaf and Harry J. Koning
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer pp. 1201-1218 Downloads
Wei Gao, Dominic Muston, Matthew Monberg, Kimmie McLaurin, Robert Hettle, Elizabeth Szamreta, Elyse Swallow, Su Zhang, Iden Kalemaj, James Signorovitch and R. Brett McQueen
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020) pp. 1219-1236 Downloads
Michael Urbich, Gary Globe, Krystallia Pantiri, Marieke Heisen, Craig Bennison, Heidi S. Wirtz and Gian Luca Di Tanna
Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome pp. 1237-1245 Downloads
Edward E. Neuberger, Josh J. Carlson and David L. Veenstra
Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering pp. 1247-1261 Downloads
Mohamed El Alili, Johanna M. Dongen, Keith S. Goldfeld, Martijn W. Heymans, Maurits W. Tulder and Judith E. Bosmans
Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data pp. 1263-1275 Downloads
Koen Degeling, Hui-Li Wong, Hendrik Koffijberg, Azim Jalali, Jeremy Shapiro, Suzanne Kosmider, Rachel Wong, Belinda Lee, Matthew Burge, Jeanne Tie, Desmond Yip, Louise Nott, Adnan Khattak, Stephanie Lim, Susan Caird, Peter Gibbs and Maarten IJzerman
Correction to: Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers pp. 1277-1277 Downloads
Risha Gidwani and Louise Russell

Volume 38, issue 10, 2020

Future of Data Analytics in the Era of the General Data Protection Regulation in Europe pp. 1021-1029 Downloads
Katarzyna Kolasa, W. Ken Redekop, Alexander Berler, Vladimir Zah and Carl V. Asche
Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development pp. 1031-1042 Downloads
Meenakshi Srinivasan, Annesha White, Ayyappa Chaturvedula, Valvanera Vozmediano, Stephan Schmidt, Leo Plouffe and La’Marcus T. Wingate
Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1043-1053 Downloads
Ben Wijnen, Nigel Armstrong, Bram Ramaekers, Willem Witlox, Marie Westwood, Debra Fayter, Steve Ryder, Titas Buksnys, Gill Worthy, Kate Misso, Sabine Grimm, Jos Kleijnen and Manuela Joore
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines pp. 1055-1070 Downloads
Bogdan Grigore, Oriana Ciani, Florian Dams, Carlo Federici, Saskia Groot, Meilin Möllenkamp, Stefan Rabbe, Kosta Shatrov, Antal Zemplenyi and Rod S. Taylor
Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies pp. 1071-1094 Downloads
Gatien Broucker, So Yoon Sim, Logan Brenzel, Margaret Gross, Bryan Patenaude and Dagna O. Constenla
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness pp. 1095-1113 Downloads
Clara Marquina, Ella Zomer, Sandra Vargas-Torres, Sophia Zoungas, Richard Ofori-Asenso, Danny Liew and Zanfina Ademi
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US pp. 1115-1121 Downloads
William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti and Gerard F. Anderson
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions pp. 1123-1133 Downloads
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri and Volker Foos
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018 pp. 1135-1145 Downloads
David D. Kim, Madison C. Silver, Natalia Kunst, Joshua T. Cohen, Daniel A. Ollendorf and Peter J. Neumann
Correction to: Calculating and Interpreting ICERs and Net Benefit pp. 1147-1147 Downloads
Mike Paulden

Volume 38, issue 9, 2020

Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review pp. 901-903 Downloads
Paul Catchpole and Victoria Barrett
Financing Drug Innovation in the US: Current Framework and Emerging Challenges pp. 905-911 Downloads
David Cutler, Noam Kirson and Genia Long
Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence? pp. 913-926 Downloads
Luiza Raquel Grazziotin, Gillian Currie, Michelle M. A. Kip, Maarten J. IJzerman, Marinka Twilt, Raymond Lee and Deborah A. Marshall
Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review pp. 927-939 Downloads
T. Joseph Mattingly, Bryan L. Love and Bilal Khokhar
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States pp. 941-951 Downloads
Sang Kyu Cho, Beenish S. Manzoor, Kavita R. Sail, Hélène Parisé, Arliene Ravelo, Sheila Shapouri, Tatyana Kapustyan, Simon Sharmokh, Suchin Virabhak, Matthew S. Davids and Scott Johnson
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM pp. 953-969 Downloads
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson and Pierre Johansen
Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis pp. 971-980 Downloads
Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, Beth K. Potter, George A. Wells and Doug Coyle
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria pp. 981-994 Downloads
Thomas O’Connell, Marric Buessing, Scott Johnson, Lufei Tu, Simu K. Thomas and Ioannis Tomazos
Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates pp. 995-1005 Downloads
Allison Portnoy, Kelsey Vaughan, Emma Clarke-Deelder, Christian Suharlim, Stephen C. Resch, Logan Brenzel and Nicolas A. Menzies
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis pp. 1007-1020 Downloads
Ning Kam, Kanila Perera, Ella Zomer, Danny Liew and Zanfina Ademi

Volume 38, issue 8, 2020

Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit? pp. 777-779 Downloads
James F. O’Mahony
Why it’s Time to Abandon the ICER pp. 781-784 Downloads
Mike Paulden
Calculating and Interpreting ICERs and Net Benefit pp. 785-807 Downloads
Mike Paulden
Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses pp. 809-818 Downloads
Michelle Q. T. Kwok, Mistura A. Kareem, Michael J. Cash, Fiona Lafferty, Katy Tobin and James F. O’Mahony
A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology pp. 819-837 Downloads
Lucy Cunnama, Gabriela B. Gomez, Mariana Siapka, Ben Herzel, Jeremy Hill, Angela Kairu, Carol Levin, Dickson Okello, Willyanne DeCormier Plosky, Inés Garcia Baena, Sedona Sweeney, Anna Vassall and Edina Sinanovic
Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States pp. 839-856 Downloads
Kristina Burström, Fitsum Sebsibe Teni, Ulf-G. Gerdtham, Reiner Leidl, Gert Helgesson, Ola Rolfson and Martin Henriksson
Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model pp. 857-869 Downloads
Jason Gordon, Oliver Darlington, Phil McEwan, Matthew Lumley, Amer Taie, Meagen Hicks, Claudie Charbonneau, Angela Blake, Neil Hawkins, Simon Goldenberg, Jonathan Otter and Mark Wilcox
Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff pp. 871-881 Downloads
Tracy A. Comans, Kim-Huong Nguyen, Julie Ratcliffe, Donna Rowen and Brendan Mulhern
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis pp. 883-892 Downloads
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, Benjamin Ettle and Tjalf Ziemssen
Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?” pp. 893-894 Downloads
Wui-Jin Koh and Robert W. Carlson
Response to Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?” pp. 895-896 Downloads
Audrey Tran and Vinay Prasad
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis pp. 897-897 Downloads
Nils-Henning Ness, Dirk Schriefer, Rocco Haase, Benjamin Ettle and Tjalf Ziemssen
Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology pp. 899-900 Downloads
Lucy Cunnama, Gabriela B. Gomez, Mariana Siapka, Ben Herzel, Jeremy Hill, Angela Kairu, Carol Levin, Dickson Okello, Willyanne DeCormier Plosky, Inés Garcia Baena, Sedona Sweeney, Anna Vassall and Edina Sinanovic

Volume 38, issue 7, 2020

International Valuation Protocol for the EQ-5D-Y-3L pp. 653-663 Downloads
Juan M. Ramos-Goñi, Mark Oppe, Elly Stolk, Koonal Shah, Simone Kreimeier, Oliver Rivero-Arias and Nancy Devlin
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations pp. 665-681 Downloads
Matthew Franklin, James Lomas and Gerry Richardson
Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review pp. 683-713 Downloads
Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs and Maarten IJzerman
Economic Costs of Myasthenia Gravis: A Systematic Review pp. 715-728 Downloads
Erik Landfeldt, Oksana Pogoryelova, Thomas Sejersen, Niklas Zethraeus, Ari Breiner and Hanns Lochmüller
Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? pp. 729-731 Downloads
Audrey A. Tran and Vinay Prasad
What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society? pp. 733-735 Downloads
R. Brett McQueen
The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating pp. 737-745 Downloads
Aaron P. Mitchell, Pranammya Dey, Jennifer A. Ohn, Sara M. Tabatabai, Michael A. Curry and Peter B. Bach
Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden pp. 747-764 Downloads
Julia Widén, Magnus Ivarsson, Lovisa Schalin, Polina Vrouchou, Matthias Schwenkglenks, Olof Heimbürger, Zanfina Ademi and C. Simone Sutherland
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study pp. 765-776 Downloads
Rose Hart, Darren Burns, Bram Ramaekers, Shijie Ren, Daniel Gladwell, Will Sullivan, Niall Davison, Owain Saunders, Indeg Sly, Theresa Cain and Dawn Lee

Volume 38, issue 6, 2020

Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 527-536 Downloads
Peter Auguste, Jill Colquitt, Martin Connock, Emma Loveman, Rachel Court, Olga Ciccarelli, Carl Counsell and Xavier Armoiry
A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway pp. 537-555 Downloads
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno and Sarah Byford
‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases pp. 557-574 Downloads
Michela Meregaglia, Amanda Whittal, Elena Nicod and Michael Drummond
A Comparison of the EQ-5D-3L and EQ-5D-5L pp. 575-591 Downloads
Alexander James Thompson and Alex James Turner
Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches pp. 593-606 Downloads
Marco Boeri, Daniel Saure, Alexander Schacht, Elisabeth Riedl and Brett Hauber
A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome pp. 607-618 Downloads
Kelly Fust, Michael Maschio, Michele Kohli, Simron Singh, D. Mark Pritchard, Florence Marteau, Peter Myrenfors and Marion Feuilly
Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa pp. 619-631 Downloads
Sedona Sweeney, Anna Vassall, Lorna Guinness, Mariana Siapka, Natsayi Chimbindi, Don Mudzengi and Gabriela B. Gomez
Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving pp. 633-643 Downloads
Petra Baji, Miklós Farkas, Dominik Golicki, Valentina Prevolnik Rupel, Renske Hoefman, Werner Brouwer, Job Exel, Zsombor Zrubka, László Gulácsi and Márta Péntek
Comment on ‘Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal’ pp. 645-648 Downloads
Ian Jacob, Karin Butler, Karolina Badora, Vanessa Gross, Annette Beiderbeck, Steve Morris and Phil McEwan
Response to Comment on “Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal” pp. 649-651 Downloads
Xavier G. L. V. Pouwels, Svenja Petersohn, Vanesa Huertas Carrera, Alastair K. Denniston, Annette Chalker, Heike Raatz, Nigel Armstrong, Willem Witlox, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen and Manuela A. Joore

Volume 38, issue 5, 2020

We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can pp. 427-429 Downloads
Elliot B. Tapper and Jagpreet Chhatwal
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 431-441 Downloads
Xavier G. L. V. Pouwels, Svenja Petersohn, Vanesa Huertas Carrera, Alastair K. Denniston, Annette Chalker, Heike Raatz, Nigel Armstrong, Dhwani Shah, Willem Witlox, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen and Manuela A. Joore
Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity pp. 443-458 Downloads
Adriënne H. Rotteveel, Mattijs S. Lambooij, Nicolaas P. A. Zuithoff, Job Exel, Karel G. M. Moons and G. Ardine Wit
Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs pp. 459-471 Downloads
Salah Ghabri, Laurent Lam, François Bocquet and Hans-Martin Spath
Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review pp. 473-484 Downloads
Matteo Ruggeri, Carlo Drago, Francesco Rosiello, Valentina Orlando and Costanza Santori
Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements pp. 485-497 Downloads
Pierre Johansen, Daniel Howard, Ryan Bishop, Søren Ilsøe Moreno and Kristine Buchholtz
Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling pp. 499-513 Downloads
Kim Dalziel, Max Catchpool, Borja García-Lorenzo, Inigo Gorostiza, Richard Norman and Oliver Rivero-Arias
Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach pp. 515-526 Downloads
Lih-Wen Mau, Jaime M. Preussler, Linda J. Burns, Susan Leppke, Navneet S. Majhail, Christa L. Meyer, Tatenda Mupfudze, Wael Saber, Patricia Steinert and David Vanness

Volume 38, issue 4, 2020

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 317-324 Downloads
Willem J. A. Witlox, Antoinette D. I. Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore and Sabine E. Grimm
Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going? pp. 325-340 Downloads
Donna Rowen, Oliver Rivero-Arias, Nancy Devlin and Julie Ratcliffe
Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review pp. 341-356 Downloads
Wilfried Guets, Hareth Al-Janabi and Lionel Perrier
Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysis pp. 357-373 Downloads
Stavros Petrou, Natnaree Krabuanrat and Kamran Khan
Estimating Age- and Sex-Specific Utility Values from the CHU9D Associated with Child and Adolescent BMI z-Score pp. 375-384 Downloads
Anagha Killedar, Thomas Lung, Stavros Petrou, Armando Teixeira-Pinto and Alison Hayes
A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity pp. 385-395 Downloads
Tim S. Grant, Darren Burns, Christopher Kiff and Dawn Lee
Determinants of Orphan Drug Prices in Germany pp. 397-411 Downloads
Franziska Worm and Charalabos-Markos Dintsios
A French Value Set for the EQ-5D-5L pp. 413-425 Downloads
Luiz Flavio Andrade, Kristina Ludwig, Juan Manuel Ramos Goni, Mark Oppe and Gérard Pouvourville

Volume 38, issue 3, 2020

Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review pp. 243-245 Downloads
Meindert Boysen and Ian Watson
After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator? pp. 247-257 Downloads
Mark Sculpher and Stephen Palmer
Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study pp. 259-267 Downloads
Elisabet Jacobsen, Dwayne Boyers and Alison Avenell
Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review pp. 269-283 Downloads
Alexander Moreno-Calderón, Thai S. Tong and Praveen Thokala
Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio pp. 285-296 Downloads
Fernando Alarid-Escudero and Karen M. Kuntz
Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan pp. 297-306 Downloads
Haruhisa Fukuda, Yoshihiko Yano, Daisuke Sato, Sachiko Ohde, Shinichi Noto, Ryo Watanabe and Osamu Takahashi
Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome pp. 307-313 Downloads
Michael Ryan, Bonnie M. K. Donato, William Irish, Christoph Gasteyger, Gilbert L’Italien and Jeffrey Laurence
Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes pp. 315-315 Downloads
Laura Panattoni, Paul M. Brown, Braden Te Ao, Mark Webster and Patrick Gladding

Volume 38, issue 2, 2020

Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices pp. 125-134 Downloads
Brendan Shaw and Jorge Mestre-Ferrandiz
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit pp. 135-141 Downloads
Christopher McCabe, Mike Paulden, Isaac Awotwe, Andrew Sutton and Peter Hall
A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders pp. 143-158 Downloads
Patrick Fahr, James Buchanan and Sarah Wordsworth
Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review pp. 159-170 Downloads
Xinyu Qian, Rachel Lee-Yin Tan, Ling-Hsiang Chuang and Nan Luo
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment pp. 171-179 Downloads
David D. Kim, Gregory F. Guzauskas, Caroline S. Bennette, Anirban Basu, David L. Veenstra, Scott D. Ramsey and Josh J. Carlson
Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada pp. 181-192 Downloads
Feng Tian, Sherilyn K. D. Houle, Mhd. Wasem Alsabbagh and William W. L. Wong
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness pp. 193-204 Downloads
Ben Kearns, John Stevens, Shijie Ren and Alan Brennan
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models pp. 205-216 Downloads
Sabine E. Grimm, Xavier Pouwels, Bram L. T. Ramaekers, Ben Wijnen, Saskia Knies, Janneke Grutters and Manuela A. Joore
Transferability of Economic Evaluations of Treatments for Advanced Melanoma pp. 217-231 Downloads
Claire Gorry, Laura McCullagh and Michael Barry
Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis pp. 233-242 Downloads
T. Joseph Mattingly, Julia F. Slejko, Eberechukwu Onukwugha, Eleanor M. Perfetto, Shyamasundaran Kottilil and C. Daniel Mullins

Volume 38, issue 1, 2020

The New and Non-Transparent Cancer Drugs Fund pp. 1-4 Downloads
Eifiona M. Wood and Dyfrig A. Hughes
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians pp. 5-24 Downloads
Alisa Likhitsup and Neehar D. Parikh
Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis pp. 25-37 Downloads
Alexander Konnopka and Hannah König
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 39-56 Downloads
Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study pp. 57-68 Downloads
Dean A. Regier, David L. Veenstra, Anirban Basu and Josh J. Carlson
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan pp. 69-84 Downloads
Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou and Ryuichi Iwakiri
Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity pp. 85-95 Downloads
Susanne Schmitz, Tatjana T. Makovski, Roisin Adams, Marjan Akker, Saverio Stranges and Maurice P. Zeegers
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes pp. 97-108 Downloads
Caitlin Smare, Khalid Lakhdari, Justin Doan, John Posnett and Sukhvinder Johal
The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation pp. 109-119 Downloads
Margrét V. Bjarnadóttir, David R. Anderson, Kislaya Prasad, Ritu Agarwal and D. Alan Nelson
Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’ pp. 121-122 Downloads
Livio Garattini and Nicholas Freemantle
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 123-123 Downloads
Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal
Page updated 2021-01-15